Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises
Authors
Keywords
-
Journal
PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages 108301
Publisher
Elsevier BV
Online
2022-10-24
DOI
10.1016/j.pharmthera.2022.108301
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epigenetics in the Diagnosis and Therapy of Malignant Melanoma
- (2022) Simeon Santourlidis et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- HDAC2 Is Involved in the Regulation of BRN3A in Melanocytes and Melanoma
- (2022) Markus V. Heppt et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genes regulated by DNA methylation are involved in distinct phenotypes during melanoma progression and are prognostic factors for patients
- (2022) Debora D’Angelo Papaiz et al. Molecular Oncology
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process
- (2022) Marine Melixetian et al. Cells
- Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
- (2022) Dusan Ruzic et al. Pharmaceutics
- Exploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics
- (2022) Michelle Y. Wang et al. ACS Chemical Biology
- Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma
- (2022) Francesca Aroldi et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Targeted Therapy for Melanomas Without BRAF V600 Mutations
- (2022) Christian Menzer et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
- (2022) Claus Garbe et al. EUROPEAN JOURNAL OF CANCER
- Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
- (2022) Kostas Palamaris et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
- (2022) Jason J Luke et al. LANCET
- Genome-wide promoter methylation profiling in a cellular model of melanoma progression reveals markers of malignancy and metastasis that predict melanoma survival
- (2022) Flávia E. Rius et al. Clinical Epigenetics
- Valproic Acid Enhances Radiosensitization via DNA Double-strand Breaks for Boronophenylalanine-mediated Neutron Capture Therapy in Melanoma Cells
- (2022) ZIH-YIN LAI et al. ANTICANCER RESEARCH
- Targeting EZH2 for cancer therapy: From current progress to novel strategies
- (2022) Jia Zeng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The Treatment of Advanced Melanoma: Therapeutic Update
- (2022) Alessia Villani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab
- (2022) Vincent T. Ma et al. Frontiers in Immunology
- Long non‐coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation
- (2021) Marine Melixetian et al. EMBO REPORTS
- The Melanocyte Lineage Factor miR-211 Promotes BRAFV600E Inhibitor Resistance
- (2021) Stephen M. Ostrowski et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Recent developments of HDAC inhibitors: Emerging indications and novel molecules
- (2021) Andrey D. Bondarev et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- lncRNA SAMMSON mediates adaptive resistance to RAF inhibition in BRAF-mutant melanoma cells
- (2021) Shujun Han et al. CANCER RESEARCH
- Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?
- (2021) Stephanie McKenna et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- (2021) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
- (2021) Andrew Bottomley et al. LANCET ONCOLOGY
- Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
- (2021) Iris Lodewijk et al. Clinical Epigenetics
- Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
- (2021) Emily J. Lelliott et al. Frontiers in Immunology
- Systemic Therapy of Metastatic Melanoma: On the Road to Cure
- (2021) Julian Steininger et al. Cancers
- HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells
- (2021) Soon-Duck Ha et al. Cells
- Advances in the discovery and development of melanoma drug therapies
- (2021) Monica Chanda et al. Expert Opinion on Drug Discovery
- Synergistic Effect of Simultaneous versus Sequential Combined Treatment of Histone Deacetylase Inhibitor Valproic Acid with Etoposide on Melanoma Cells
- (2021) Yueh-Ming Shyu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Non-coding RNAs in melanoma: Biological functions and potential clinical applications
- (2021) Qiu Peng et al. Molecular Therapy-Oncolytics
- Epigenetic Regulation in Melanoma: Facts and Hopes
- (2021) Emilio Francesco Giunta et al. Cells
- Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers
- (2021) Maria Gracia-Hernandez et al. Cancers
- The Functional Role of Long Non-Coding RNAs in Melanoma
- (2021) Michal Wozniak et al. Cancers
- Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
- (2020) Axel Hauschild et al. EUROPEAN JOURNAL OF CANCER
- An overview of binimetinib for the treatment of melanoma
- (2020) Pol Specenier EXPERT OPINION ON PHARMACOTHERAPY
- The miRNAs Role in Melanoma and in Its Resistance to Therapy
- (2020) Francesca Varrone et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Long Noncoding RNA X-Inactive Specific Transcript Facilitates Cellular Functions in Melanoma via miR-139-5p/ROCK1 Pathway
- (2020) Ke Tian et al. OncoTargets and Therapy
- Correction to: LncRNA MEG3 promotes melanoma growth, metastasis and formation through modulating miR-21/E-cadherin axis
- (2020) Liangcai Wu et al. Cancer Cell International
- Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma
- (2020) Vincent T. Ma et al. FACIAL PLASTIC SURGERY
- Systemic Therapy for Melanoma: ASCO Guideline
- (2020) Rahul Seth et al. JOURNAL OF CLINICAL ONCOLOGY
- Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation
- (2020) Jiahui Tng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R
- (2020) Suresh Bugide et al. Oncogenesis
- Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlates with Response to B-Raf and MEK Inhibition and with Proliferation in Melanocytic Tumors
- (2020) Maximilian Gassenmaier et al. AMERICAN JOURNAL OF PATHOLOGY
- ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee
- (2020) U. Keilholz et al. ANNALS OF ONCOLOGY
- Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies
- (2020) Shaghayegh Haghjooy Javanmard et al. Cancer Cell International
- Towards a more precise therapy in cancer: Exploring epigenetic complexity
- (2020) Fernando P. Cossío et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Cancer stem cells, epigenetics, tumor microenvironment and future therapeutics in cutaneous malignant melanoma: a review
- (2020) Georgia Kyriakou et al. Future Oncology
- MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
- (2020) Maria Letizia Motti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch
- (2020) Wen Juan Tu et al. Frontiers in Immunology
- Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
- (2020) Minjeong Yeon et al. Frontiers in Cell and Developmental Biology
- The tumor microenvironment
- (2020) Nicole M. Anderson et al. CURRENT BIOLOGY
- The critical roles of lncRNAs in the pathogenesis of melanoma
- (2020) Amin Safa et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- (2020) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA-211 modulates the DUSP6-ERK5 signaling axis to promote BRAFV600E-driven melanoma growth in vivo and BRAF/MEK inhibitor resistance
- (2020) Bongyong Lee et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Importance of microRNAs in Skin Oncogenesis and Their Suitability as Agents and Targets for Topical Therapy
- (2020) Dennis Gerloff et al. SKIN PHARMACOLOGY AND PHYSIOLOGY
- Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
- (2020) Lokeswari P. Tangella et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency
- (2020) Olga A. Patutina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma
- (2020) Manfred Kunz et al. JOURNAL OF NANOBIOTECHNOLOGY
- The Non-Coding Landscape of Cutaneous Malignant Melanoma: A Possible Route to Efficient Targeted Therapy
- (2020) Andreea D. Lazăr et al. Cancers
- Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival
- (2019) Alice Indini et al. Future Oncology
- Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure–Activity Relations of New Inhibitors of HDAC and/or Tubulin Function
- (2019) Florian Schmitt et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations
- (2019) Claudia TROJANIELLO et al. Expert Review of Clinical Pharmacology
- HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics
- (2019) Andressa S. Laino et al. Journal for ImmunoTherapy of Cancer
- Updates to the antitumor mechanism of oncolytic virus
- (2019) Yang Bai et al. Thoracic Cancer
- MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas
- (2019) Ophélia Maertens et al. Cancer Discovery
- Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker
- (2019) Chiara Zagni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)
- (2019) Viola Franke et al. INTERNATIONAL JOURNAL OF CANCER
- MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma
- (2019) Edward Kim et al. CANCER RESEARCH
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade
- (2019) Huitong Ruan et al. ADVANCED MATERIALS
- HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
- (2019) Michael F. Emmons et al. CANCER RESEARCH
- Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target
- (2019) Elias Orouji et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
- (2019) Abdullah Al Emran et al. TRENDS IN IMMUNOLOGY
- Systemic Therapies for Advanced Melanoma
- (2019) Leonora Bomar et al. DERMATOLOGIC CLINICS
- Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors
- (2019) Chunhui Cheng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
- (2019) Tessa Knox et al. Scientific Reports
- LNMAT1 Promotes Invasion-Metastasis Cascade in Malignant Melanoma by Epigenetically Suppressing CADM1 Expression
- (2019) Kuanhou Mou et al. Frontiers in Oncology
- Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial
- (2019) Anna Maria Di Giacomo et al. CLINICAL CANCER RESEARCH
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of V600E and V600K BRAF-Mutant Melanoma
- (2019) Alexandra M. Haugh et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity
- (2019) Prakruti Trivedi et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- DNA hypermethylation is associated with invasive phenotype of malignant melanoma
- (2019) Viktória Koroknai et al. EXPERIMENTAL DERMATOLOGY
- An evaluation of encorafenib for the treatment of melanoma
- (2019) Michael J. Carr et al. EXPERT OPINION ON PHARMACOTHERAPY
- Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
- (2019) Anne Catherine Bretz et al. Journal for ImmunoTherapy of Cancer
- Role of Mammalian DNA Methyltransferases in Development
- (2019) Zhiyuan Chen et al. Annual Review of Biochemistry
- The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker
- (2019) Feifei Yang et al. CHEMISTRY & BIODIVERSITY
- The timeline of epigenetic drug discovery: from reality to dreams
- (2019) A. Ganesan et al. Clinical Epigenetics
- Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma
- (2018) Timothy Budden et al. BMC CANCER
- Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma
- (2018) Yong Yu et al. CANCER CELL
- LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
- (2018) Wanqiang Sheng et al. CELL
- Long non-coding RNAs in melanoma
- (2018) Xin Yu et al. CELL PROLIFERATION
- Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
- (2018) Ileabett M Echevarría‐Vargas et al. EMBO Molecular Medicine
- Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents
- (2018) Rui Xie et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- MicroRNA-21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin: An in vitro study
- (2018) Hai-Lin Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer
- (2018) Hongyu Liu et al. Molecular Cancer
- Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression
- (2018) Ke Li et al. ONCOGENE
- From chemo-prevention to epigenetic regulation: The role of isothiocyanates in skin cancer prevention
- (2018) Melina Mitsiogianni et al. PHARMACOLOGY & THERAPEUTICS
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance
- (2018) Farzana Ahmed et al. Frontiers in Oncology
- CASC2: An emerging tumour-suppressing long noncoding RNA in human cancers and melanoma
- (2018) Xin Yu et al. CELL PROLIFERATION
- Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects
- (2018) Prakruti Trivedi et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Melanoma treatment: from conventional to nanotechnology
- (2018) Harshita Mishra et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Melanoma
- (2018) Dirk Schadendorf et al. LANCET
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models
- (2018) Daniela Dettori et al. MOLECULAR THERAPY
- The Role of Oncolytic Viruses in the Treatment of Melanoma
- (2018) Claire-Audrey Y. Bayan et al. Current Oncology Reports
- SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
- (2018) Thomas Strub et al. Nature Communications
- Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A
- (2018) ELIZABETH A. MAZZIO et al. Cancer Genomics & Proteomics
- Basal Cell Carcinoma Arises from Interfollicular Layer of Epidermis
- (2018) Sukmawati Tansil Tan et al. Journal of Oncology
- Relative toxicity of mood stabilisers and antipsychotics: case fatality and fatal toxicity associated with self-poisoning
- (2018) Anne E. Ferrey et al. BMC Psychiatry
- miR-146a Controls Immune Response in the Melanoma Microenvironment
- (2018) Justin Mastroianni et al. CANCER RESEARCH
- Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
- (2018) Luke D. Rothermel et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma
- (2018) Veronica Huber et al. JOURNAL OF CLINICAL INVESTIGATION
- The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
- (2018) N.P. Graf et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations
- (2018) Xiaoni Liu et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- New insights in melanoma resistance to BRAF inhibitors: a role for microRNAs
- (2018) Marta Díaz-Martínez et al. Oncotarget
- Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
- (2018) Paolo A. Ascierto et al. JAMA Oncology
- The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents
- (2017) Rui Xie et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Targeting breast cancer stem cells by novel HDAC3-selective inhibitors
- (2017) Hao-Yu Hsieh et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Antitumor activity and expression profiles of genes induced by sulforaphane in human melanoma cells
- (2017) Paola Arcidiacono et al. EUROPEAN JOURNAL OF NUTRITION
- HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
- (2017) Stuart J. Gallagher et al. INTERNATIONAL JOURNAL OF CANCER
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The use of immunotherapy in the treatment of melanoma
- (2017) Tala Achkar et al. Journal of Hematology & Oncology
- MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma
- (2017) Matias A. Bustos et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma
- (2017) Valeria Lucarini et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells
- (2017) Ludovic Halby et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing
- (2017) Sankhiros Babapoor et al. LABORATORY INVESTIGATION
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
- (2017) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Towards therapeutic advances in melanoma management: An overview
- (2017) Swarnendra Singh et al. LIFE SCIENCES
- Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood
- (2017) Julia Joung et al. NATURE
- SWI/SNF complex in cancer
- (2017) Chao Lu et al. NATURE GENETICS
- The DNA methyltransferase family: a versatile toolkit for epigenetic regulation
- (2017) Frank Lyko NATURE REVIEWS GENETICS
- The cancer epigenome: Concepts, challenges, and therapeutic opportunities
- (2017) Mark A. Dawson SCIENCE
- Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models
- (2017) Maurício T. Tavares et al. ACS Medicinal Chemistry Letters
- Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study
- (2017) Yousef Zakharia et al. Oncotarget
- MicroRNAs in melanoma development and resistance to target therapy
- (2017) Luigi Fattore et al. Oncotarget
- Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells
- (2017) Marianna Vitiello et al. Oncotarget
- HDAC inhibitors enhance the immunotherapy response of melanoma cells
- (2017) Laurence Booth et al. Oncotarget
- The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
- (2017) Daniel Zingg et al. Cell Reports
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
- (2017) Goran Micevic et al. Clinical Epigenetics
- Epigenetics in Human Melanoma
- (2017) Paul M. Howell et al. Cancer Control
- Epigenetic Therapeutics: A New Weapon in the War Against Cancer
- (2016) Nita Ahuja et al. Annual Review of Medicine
- Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity
- (2016) María Díaz-Núñez et al. BMC CANCER
- Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance
- (2016) A. Krumm et al. CANCER RESEARCH
- The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
- (2016) Alex Kim et al. Expert Opinion on Drug Discovery
- Pro-Proliferative Function of Mitochondrial Sirtuin Deacetylase SIRT3 in Human Melanoma
- (2016) Jasmine George et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- LINE-1 hypomethylation and mutational status in cutaneous melanomas
- (2016) Dimitrius T Pramio et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells
- (2016) Jiaqi Liu et al. Journal of Translational Medicine
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- MicroRNA-21 regulates the ERK/NF-κB signaling pathway to affect the proliferation, migration, and apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN
- (2016) Xu-Hua Mao et al. MOLECULAR CARCINOGENESIS
- Melanoma addiction to the long non-coding RNA SAMMSON
- (2016) Eleonora Leucci et al. NATURE
- Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation
- (2016) Min Pan et al. NATURE CELL BIOLOGY
- Histone deacetylase 6 structure and molecular basis of catalysis and inhibition
- (2016) Yang Hai et al. Nature Chemical Biology
- Targeting the cancer epigenome for therapy
- (2016) Peter A. Jones et al. NATURE REVIEWS GENETICS
- The molecular hallmarks of epigenetic control
- (2016) C. David Allis et al. NATURE REVIEWS GENETICS
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA methylation-induced E-cadherin silencing is correlated with the clinicopathological features of melanoma
- (2016) MARIO VENZA et al. ONCOLOGY REPORTS
- ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation
- (2016) Ueihuei Peng et al. ONCOLOGY REPORTS
- The emerging role of long non-coding RNAs in cutaneous melanoma
- (2016) Eleonora Leucci et al. Pigment Cell & Melanoma Research
- DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines
- (2016) Ya-Ping Chen et al. TUMOR BIOLOGY
- In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype
- (2016) D. Bossi et al. Cancer Discovery
- RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma
- (2016) Lucas Goedert et al. Oncotarget
- The quest for an effective and safe personalized cell therapy using epigenetic tools
- (2016) T. A. L. Brevini et al. Clinical Epigenetics
- A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
- (2016) Jeannine Diesch et al. Clinical Epigenetics
- A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
- (2016) Nageatte Ibrahim et al. Cancer Medicine
- Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy
- (2016) Prasun J. Mishra et al. PLoS One
- DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension
- (2015) Jonathan D. Licht CELL
- Hydroxamate-Based Histone Deacetylase Inhibitors Can Protect Neurons from Oxidative Stress via a Histone Deacetylase-Independent Catalase-Like Mechanism
- (2015) David E. Olson et al. CHEMISTRY & BIOLOGY
- Histone deacetylases: structural determinants of inhibitor selectivity
- (2015) Carmina Micelli et al. DRUG DISCOVERY TODAY
- Epigenetic regulation in human melanoma: past and future
- (2015) Debina Sarkar et al. Epigenetics
- Vemurafenib for the treatment ofBRAFmutant metastatic melanoma
- (2015) Juan Martin-Liberal et al. Future Oncology
- Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma
- (2015) Douglas B Johnson et al. Immunotherapy
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- LINE-1 hypermethylation in peripheral blood of cutaneous melanoma patients is associated with metastasis
- (2015) Érica S.S. De Araújo et al. MELANOMA RESEARCH
- Quantitative Histone Mass Spectrometry Identifies Elevated Histone H3 Lysine 27 (Lys27) Trimethylation in Melanoma
- (2015) Deepanwita Sengupta et al. MOLECULAR & CELLULAR PROTEOMICS
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjusting for the Confounding Effects of Treatment Switching--The BREAK-3 Trial: Dabrafenib Versus Dacarbazine
- (2015) N. R. Latimer et al. ONCOLOGIST
- Epigenetic therapy as a novel approach in hepatocellular carcinoma
- (2015) Ioannis Anestopoulos et al. PHARMACOLOGY & THERAPEUTICS
- Circulating epigenetic biomarkers in melanoma
- (2015) Yu Xin et al. TUMOR BIOLOGY
- Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives
- (2015) Diego M Marzese et al. Epigenomics
- The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
- (2015) Daniel Zingg et al. Nature Communications
- Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b
- (2015) Elisabetta Vergani et al. Oncotarget
- Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
- (2015) Anja Heinemann et al. Oncotarget
- SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells
- (2015) Mickaël Ohanna et al. Oncotarget
- Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients
- (2014) Nathaniel H. Fleming et al. CANCER
- Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)
- (2014) Chang Xia et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sirtuin deacetylases: A new target for melanoma management
- (2014) Melissa J Wilking et al. CELL CYCLE
- RASSF6exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells
- (2014) Jessica J Mezzanotte et al. Epigenetics
- Hydralazine–valproate: a repositioned drug combination for the epigenetic therapy of cancer
- (2014) Alfonso Dueñas-Gonzalez et al. Expert Opinion on Drug Metabolism & Toxicology
- HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis
- (2014) Manjola Balliu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells
- (2014) Yukihiko Kato et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- SIRT1 Regulates Lamellipodium Extension and Migration of Melanoma Cells
- (2014) Risa Kunimoto et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells
- (2014) Sergio Valente et al. JOURNAL OF MEDICINAL CHEMISTRY
- Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma
- (2014) Sara Harcharik et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Melanoma epigenetics: novel mechanisms, markers and medicines
- (2014) Jonathan J Lee et al. LABORATORY INVESTIGATION
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity
- (2014) P K Bajpe et al. ONCOGENE
- Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
- (2014) Prithviraj Bose et al. PHARMACOLOGY & THERAPEUTICS
- Epigenetics of human melanoma: promises and challenges
- (2014) A. Besaratinia et al. Journal of Molecular Cell Biology
- Writers and Readers of Histone Acetylation: Structure, Mechanism, and Inhibition
- (2014) R. Marmorstein et al. Cold Spring Harbor Perspectives in Biology
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
- (2013) Alexander Roesch et al. CANCER CELL
- Interplay between the Cancer Genome and Epigenome
- (2013) Hui Shen et al. CELL
- DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
- (2013) Varinder Singh et al. CURRENT CANCER DRUG TARGETS
- Signal Transduction in Human Cutaneous Melanoma and Target Drugs
- (2013) Anatoly Uzdensky et al. CURRENT CANCER DRUG TARGETS
- Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring
- (2013) L. Guandalini et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Epigenetics of melanoma: implications for immune-based therapies
- (2013) Elisabetta Fratta et al. Immunotherapy
- Discovery of Potent, Isoform-Selective Inhibitors of Histone Deacetylase Containing Chiral Heterocyclic Capping Groups and a N-(2-Aminophenyl)benzamide Binding Unit
- (2013) Charles M. Marson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015
- (2013) M. Arnold et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity
- (2013) David M. Woods et al. MELANOMA RESEARCH
- Structure and function of long noncoding RNAs in epigenetic regulation
- (2013) Tim R Mercer et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Effectiveness of the Histone Deacetylase Inhibitor (S)-2 against LNCaP and PC3 Human Prostate Cancer Cells
- (2013) Anna Laurenzana et al. PLoS One
- Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3
- (2013) F Lai et al. Cell Death & Disease
- Long Noncoding RNA HOTAIR Is Associated with Motility, Invasion, and Metastatic Potential of Metastatic Melanoma
- (2013) Lihua Tang et al. Biomed Research International
- Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
- (2013) Antonino Grassadonia et al. Cancers
- Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune
- (2012) Karin van den Hurk et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- DNA methylation inhibitors in cancer: Recent and future approaches
- (2012) Christina Gros et al. BIOCHIMIE
- Epigenomics of cancer – emerging new concepts
- (2012) Melanie R. Hassler et al. BIOCHIMIE
- The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C6 position
- (2012) Sun Ea Choi et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Selenium-containing histone deacetylase inhibitors for melanoma management
- (2012) Raghavendra Gowda et al. CANCER BIOLOGY & THERAPY
- Targeting Mutant BRAF in Melanoma
- (2012) Ragini Kudchadkar et al. CANCER JOURNAL
- Cancer Epigenetics: From Mechanism to Therapy
- (2012) Mark A. Dawson et al. CELL
- Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
- (2012) Alexander M.M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- AIM1 and LINE-1 Epigenetic Aberrations in Tumor and Serum Relate to Melanoma Progression and Disease Outcome
- (2012) Sojun Hoshimoto et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- miR-137 Inhibits the Invasion of Melanoma Cells through Downregulation of Multiple Oncogenic Target Genes
- (2012) Chonglin Luo et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth
- (2012) Joel A. Bergman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis
- (2012) Daniel J. Lindner et al. MATRIX BIOLOGY
- JARID1B expression in human melanoma and benign melanocytic skin lesions
- (2012) Łukasz Kuźbicki et al. MELANOMA RESEARCH
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells
- (2012) I. Venza et al. Pigment Cell & Melanoma Research
- The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma
- (2011) Li Jiang et al. ACTA HISTOCHEMICA
- Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide
- (2011) J Chang et al. BRITISH JOURNAL OF CANCER
- miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions
- (2011) V Grignol et al. BRITISH JOURNAL OF CANCER
- Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis
- (2011) Charbel Darido et al. CANCER CELL
- Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D
- (2011) A. Heinemann et al. CANCER RESEARCH
- Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma
- (2011) Khelifa Arab et al. CARCINOGENESIS
- Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer
- (2011) Karrune V Woan et al. IMMUNOLOGY AND CELL BIOLOGY
- Immunomodulatory cytokines as therapeutic agents for melanoma
- (2011) Courtney Nicholas et al. Immunotherapy
- Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukaemia cells
- (2011) C. Cellai et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker
- (2011) Hisashi Kanemaru et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- RASSF10 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin but Uncommon in Nevus Cell Nevi
- (2011) Peter Helmbold et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients
- (2011) Luca Sigalotti et al. Journal of Translational Medicine
- MicroRNA regulation of melanoma progression
- (2011) Vanessa F. Bonazzi et al. MELANOMA RESEARCH
- EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression
- (2011) T. Fan et al. MOLECULAR CANCER RESEARCH
- The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset
- (2011) Craig J. Ceol et al. NATURE
- AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas
- (2011) M. L. Bush et al. NEURO-ONCOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- UV wavelength-dependent DNA damage and human non-melanoma and melanoma skin cancer
- (2011) Gerd P. Pfeifer et al. PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES
- DNA-methylation profiling distinguishes malignant melanomas from benign nevi
- (2011) Kathleen Conway et al. Pigment Cell & Melanoma Research
- Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy
- (2011) Zhuo-jia Chen et al. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
- Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
- (2010) Gajanan S. Inamdar et al. BIOCHEMICAL PHARMACOLOGY
- Genome-wide hypomethylation in cancer may be a passive consequence of transformation
- (2010) Laurence Wild et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry
- (2010) María Berdasco et al. DEVELOPMENTAL CELL
- Cancer/Testis Antigen CAGE Exerts Negative Regulation on p53 Expression through HDAC2 and Confers Resistance to Anti-cancer Drugs
- (2010) Youngmi Kim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression
- (2010) Mei Yi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Aberrant DNA methylation in malignant melanoma
- (2010) Carolina Schinke et al. MELANOMA RESEARCH
- Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation
- (2010) Giovanni L Gravina et al. Molecular Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-Melanoma Effects of Vorinostat in Combination with Polyphenolic Antioxidant (−)-Epigallocatechin-3-Gallate (EGCG)
- (2010) Minakshi Nihal et al. PHARMACEUTICAL RESEARCH
- miR-148 Regulates Mitf in Melanoma Cells
- (2010) Benedikta S. Haflidadóttir et al. PLoS One
- MicroRNA-200 Family Members Differentially Regulate Morphological Plasticity and Mode of Melanoma Cell Invasion
- (2010) Ilan Elson-Schwab et al. PLoS One
- A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways
- (2009) Jung Jin Hwang et al. ANTI-CANCER DRUGS
- SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors
- (2009) Dhimant Desai et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells
- (2009) Madhavi Billam et al. BREAST CANCER RESEARCH AND TREATMENT
- Epigenetics in cancer
- (2009) S. Sharma et al. CARCINOGENESIS
- CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma
- (2009) A. Tanemura et al. CLINICAL CANCER RESEARCH
- Carnitine in the treatment of valproic acid-induced toxicity
- (2009) Philippe E.R. Lheureux et al. CLINICAL TOXICOLOGY
- Methylation of PTEN as a Prognostic Factor in Malignant Melanoma of the Skin
- (2009) Christoph Lahtz et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- CpG island methylation profiling in human melanoma cell lines
- (2009) Carmen S. Tellez et al. MELANOMA RESEARCH
- DNA hypomethylation in cancer cells
- (2009) Melanie Ehrlich Epigenomics
- Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents
- (2008) L. Guandalini et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- MicroRNA-137 Targets Microphthalmia-Associated Transcription Factor in Melanoma Cell Lines
- (2008) L. T. Bemis et al. CANCER RESEARCH
- The Promyelocytic Leukemia Zinc Finger-MicroRNA-221/-222 Pathway Controls Melanoma Progression through Multiple Oncogenic Mechanisms
- (2008) F. Felicetti et al. CANCER RESEARCH
- MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth
- (2008) Julia Schultz et al. CELL RESEARCH
- Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review
- (2008) M. F. B. Silva et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Transcriptional Modulation Using HDACi Depsipeptide Promotes Immune Cell-Mediated Tumor Destruction of Murine B16 Melanoma
- (2008) Takashi Murakami et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Optimization of Activity-Based Probes for Proteomic Profiling of Histone Deacetylase Complexes
- (2008) Cleo M. Salisbury et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling
- (2008) Suhu Liu et al. Pigment Cell & Melanoma Research
- Melanoma and the tumor microenvironment
- (2008) Jessie Villanueva et al. Current Oncology Reports
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now